论文部分内容阅读
目的:探讨低强度华法林抗凝治疗75岁以上房颤患者疗效及安全性。方法:研究组给予低强度华法林抗凝,对照组给予标准强度华法林抗凝。对两组75岁以上房颤患者给予24个月有效随访,记录各组抗凝效果及华法林药物相关不良反应发生率。结果:两组75岁以上房颤患者经不同强度华法林抗凝治疗后均顺利完成24个月有效随访(随访成功率100.00%),其中研究组栓塞发生率(17.86%)与对照组(栓塞发生率10.71%)对比结果 P>0.05,提示两组抗凝效果均较为理想;研究组华法林相关不良反应发生率(21.43%)显著低于对照组(53.57%,P<0.05),提示研究组用药安全性较优。结论:对75岁以上房颤患者给予低强度华法林抗凝可获得较为满意的有效性及安全性,有利于保障患者生活质量及生命安全。
Objective: To investigate the efficacy and safety of low-intensity warfarin anticoagulation in patients over 75 years old with atrial fibrillation. Methods: The study group was given low-intensity warfarin anticoagulation, and the control group was given standard-intensity warfarin. Two groups of patients with AF over 75 years of age were given 24 months effective follow-up, recorded the anticoagulant effect of each group and warfarin drug-related adverse reactions. Results: Two groups of patients with atrial fibrillation more than 75 years of age after warfarin anticoagulation therapy were successfully completed 24 months follow-up (follow-up success rate was 100.00%), in which the incidence of embolization (17.86%) in the study group and the control group Rate of 10.71%) compared with the results of P> 0.05, suggesting that the two groups of anticoagulant effect were ideal; the incidence of warfarin-related adverse reactions in the study group (21.43%) was significantly lower than the control group (53.57%, P <0.05) Group medication safety is better. Conclusion: The low-intensity warfarin anticoagulation given to patients with atrial fibrillation more than 75 years old can achieve more satisfactory efficacy and safety, which helps to ensure the quality of life and safety of patients.